Freshly prepared 0.1% nanoparticle curcumin mouthwash,
does it really help with Prevention of oral-mucositis severity during head-and-neck radiotherapy?
research showsGrade D with 30 points. In a 74-person triple-blind trial, 0.1% nanoparticle curcumin mouthwash delayed onset by about two weeks, but did not significantly reduce severe mucositis versus 0.15% benzydamine.
ads claimA delayed onset cannot become proof of preventing severe mucositis or guaranteeing uninterrupted cancer therapy.
Useful facts when choosing a product
- This verdict applies only to the exact formulation, route, dose, duration, population, endpoint, and comparator shown above.
- Conventional curcumin, turmeric powder, nano or micellar products, phospholipid phytosomes, piperine combinations, swallowed products, and topical oral products are not interchangeable.
- Caution. Short-term tolerability appeared similar in a small trial, but long-term safety, absorption, and preparation-quality data for a freshly compounded nanoparticle rinse are limited.
Chamgap Semantic Classification Code
Permanent code issued
K.nanocurcumin-mouthwash.topical-oral.severe-oral-mucositis.prevent.activeNonstandard topical therapy > Nanocurcumin mouthwash > Topical oral > Severe oral mucositis > Prevention claim > Active benzydamine control
Issued for the null WHO-severity claim; delayed onset and swallowed curcumin remain separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | K · Folk or alternative practice |
|---|---|
| Canonical ingredient or intervention | Nanocurcumin mouthwash |
| Source or part used | Nanoparticle curcumin derived from Curcuma longa |
| Formulation or processing | Freshly prepared 0.1% mouthwash |
| Route | Topical oral rinse and spit |
| Dose | 0.1% mouthwash; volume and frequency per trial protocol |
| Duration | Six weeks during radiotherapy |
| Population | Adults receiving head-and-neck radiotherapy |
| Effect or condition | Prevention of severe oral mucositis |
| Primary endpoint | Severe oral mucositis by WHO criteria |
| Comparator | 0.15% benzydamine mouthwash |
| Duplicate-detection key | nanocurcumin|0.1-percent-mouthwash|topical-oral|adult-head-neck-radiotherapy|severe-mucositis-prevention|6-weeks |
What the research actually shows
The trial directly compared 0.1% nanoparticle curcumin with 0.15% benzydamine for six weeks.
Why this is classified as D (30)
The selected severity claim was null, and the small six-week active-control-only design yields D with 30 points.
Counterpoint. Possible delayed onset and similarity to benzydamine prevent saying it did nothing, but neither superiority nor equivalence was established.
Rejudgment record. Independent Codex cross-check — One formulation, one route, one population, one claim, one principal endpoint and comparator
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Effectiveness of curcumin mouthwash on radiation-induced oral mucositis among head and neck cancer patients: A triple-blind, pilot randomised controlled trial | Triple-blind, active-controlled pilot randomized trial, with modified intention-to-treat (mITT) and per-protocol (PP) analyses. | Randomized, analyzed, and completed denominators are kept distinct where reported. | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint is preserved; secondary and mechanistic outcomes remain separate. | The verified numerical result is preserved in the English reader answer and rationale; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and verified analysis limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Evidence date: 2026-09-08 · Corrections: 1
Correction log — 1
Corrections applied to this verdict, in chronological order. Changes are logged, not erased.
- 2026-09-14 · English evidence-table placeholder correction — Replaced 1 generic English evidence-table placeholder field with specific source-bound translations of the retained Korean record. No new research or medical reassessment was performed; grade, score, citations, and evidence date are unchanged. (grade D unchanged)
Cite this verdict
[Chamgap] Curcumin Mouthwash for Radiation Mucositis Severity—No Evidence It Was Better Than Benzydamine — Evidence Grade D·30. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/topical-oral-nanocurcumin-mouthwash-radiation-mucositis-severity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.